These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23507769)

  • 1. Rifaximin therapy and Clostridium difficile infection: a note of caution.
    Zullo A; Ridola L; Hassan C
    J Clin Gastroenterol; 2013 Sep; 47(8):737. PubMed ID: 23507769
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis.
    Neff GW; Jones M; Jonas M; Ravinuthala R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2013 Feb; 47(2):188-92. PubMed ID: 23314671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea.
    Berman AL
    J Clin Gastroenterol; 2007; 41(10):932-3. PubMed ID: 18090164
    [No Abstract]   [Full Text] [Related]  

  • 4. Rifaximin in the treatment of recurrent Clostridium difficile infection.
    Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ
    Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
    Kokkotou E; Moss AC; Michos A; Espinoza D; Cloud JW; Mustafa N; O'Brien M; Pothoulakis C; Kelly CP
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1121-6. PubMed ID: 18195066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal Microbiota Transplant: Treatment Options for Clostridium difficile Infection in the Intensive Care Unit.
    Han S; Shannahan S; Pellish R
    J Intensive Care Med; 2016 Oct; 31(9):577-86. PubMed ID: 26141116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: prolonged remission from hepatic encephalopathy with rifaximin.
    Orr JG; Hudson M
    Aliment Pharmacol Ther; 2015 Jan; 41(2):228. PubMed ID: 25511766
    [No Abstract]   [Full Text] [Related]  

  • 9. [Rifaximin for hepatic encephalopathy in children. Case report].
    Malla I; Torres Cerino V; Villa A; Cheang Y; Giacove G; Pedreira A; Silva M
    Arch Argent Pediatr; 2011 Dec; 109(6):e113-5. PubMed ID: 22231877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifaximin: an alternative for the treatment of hepatic encephalopathy.
    Rigali VT
    Conn Med; 2006 Sep; 70(8):499-501. PubMed ID: 17089807
    [No Abstract]   [Full Text] [Related]  

  • 11. [Intestine specific broad spectrum antibiotic. Rifaximin: therapy option in hepatic encephalopathy].
    MMW Fortschr Med; 2014 Feb; 156(3):64-5. PubMed ID: 24938070
    [No Abstract]   [Full Text] [Related]  

  • 12. Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy.
    Kok B; Foxton MR; Clough C; Shawcross DL
    Hepatology; 2013 Oct; 58(4):1516-7. PubMed ID: 23471844
    [No Abstract]   [Full Text] [Related]  

  • 13. Outbreak of Clostridium difficile infection and gatifloxacin use in a long-term care facility.
    Mohr J
    Clin Infect Dis; 2004 Sep; 39(6):875-6; author reply 876-7. PubMed ID: 15472828
    [No Abstract]   [Full Text] [Related]  

  • 14. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
    Williams R; Bass N
    Rev Gastroenterol Disord; 2005; 5 Suppl 1():S10-8. PubMed ID: 15976747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rifaximin in the treatment of hepatic encephalopathy].
    Lata J; Hůlek P; Fejfar T; Spicák J; Drastich P; Marecek Z; Brůha R; Husová L; Senkyrík M
    Vnitr Lek; 2002 Jun; 48(6):578-82. PubMed ID: 12132365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapies in the treatment of Clostridium difficile-associated disease.
    Jodlowski TZ; Oehler R; Kam LW; Melnychuk I
    Ann Pharmacother; 2006 Dec; 40(12):2164-9. PubMed ID: 17119105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.
    Johnson S; Schriever C; Patel U; Patel T; Hecht DW; Gerding DN
    Anaerobe; 2009 Dec; 15(6):290-1. PubMed ID: 19698797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of rifaximin in management of hepatic encephalopathy.
    Wahib AA; El-Deen Salem MN; Ahmed MA; El-Dessouky YM; El-Tiby DM; El-Mola K; El-Sayed AM
    J Egypt Soc Parasitol; 2014 Dec; 44(3):677-85. PubMed ID: 25643509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifaximin for the treatment of hepatic encephalopathy.
    Lawrence KR; Klee JA
    Pharmacotherapy; 2008 Aug; 28(8):1019-32. PubMed ID: 18657018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series.
    Neff G; Zacharias V; Kaiser TE; Gaddis A; Kemmer N
    Liver Transpl; 2010 Aug; 16(8):960-3. PubMed ID: 20677286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.